Login
Companies $AMRX
$21.23 +$0.00 (0.0%) After hours
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc.

amneal.com

How Do They Make Money?

Customers buy finished medicines directly or through distributors and pay within one year after products ship or are delivered. The company also licenses product rights and can earn later sales-based milestones and royalties.

revenue
SegmentShareRevenue
Affordable Medicines
Sold outright

58%
FY2022: 65%
Specialty
Sold outright

18%
FY2022: 17%
AvKARE
Sold outright

25%
FY2022: 18%

Who Are Their Customers?

Most Affordable Medicines products go through wholesalers, group purchasing organizations, retail and mail-order pharmacies; sterile injectables and biosimilars also go through specialty distributors, with some direct sales to hospitals and institutions. Specialty representatives promote branded medicines to physicians, while AvKARE serves government agencies and retail and institutional buyers.

Do Revenues Turn Into Profits?

Yes. It kept 2 cents of every revenue dollar as net income in FY2025 and turned 9 cents into free cash flow.

Operating income, FY2025
13% of revenue
▲ +58% vs FY2024 ($249.3M, 9%)
Net income, FY2025
2% of revenue
▲ Turned profitable vs FY2024 (−$116.9M, −4%)
Free cash flow, FY2025
9% of revenue
▲ +11% vs FY2024 ($243.2M, 9%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +10%
vs $784.5M in Q3 FY2025
Net income
▼ Turned to a loss
vs $2.4M in Q3 FY2025
Affordable Medicines share of revenue vs 58.7% in Q3 FY2025
  • Aug 10, 2026 Completed the acquisition of Kashiv BioSciences The deal combines biosimilar research, development, manufacturing, and commercialization capabilities.
  • Jul 30, 2026 Raised 2026 full-year guidance Net revenue guidance increased to $3.10 billion - $3.20 billion from $3.05 billion - $3.15 billion.

Growing. Revenue grew 44% in 4 years, from $2.1B in FY2021 to $3B in FY2025, about 10% a year.

Biosimilar portfolio The older report described an initial oncology biosimilar portfolio; the latest report adds denosumab biosimilars and describes a broader set of commercially available biosimilars.

Specialty products The older report listed Rytary, Unithroid, and Lyvispah; the latest report also describes CREXONT and a Brekiya autoinjector in the Specialty portfolio.

Revenue over time
Affordable Medicines Specialty AvKARE Generics
$5B$2.5B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support